GlycoNex Doses First Patient in Phase I Trial of GNX1021, Advancing Its Glycan-Directed ADC into Clinical Development

Phase 1GNX1021Positive

AI Analysis

Summary

GlycoNex Inc. announced the first patient dosing in the Phase I clinical trial of GNX1021, a novel glycan-targeting antibody-drug conjugate, marking the advancement of the program into clinical development in Japan.

Clinical Trial Data

Phase

Phase 1

Outcome Details

First patient dosed in FIH Phase I trial

Importance:5/10

Sentiment:

0.70

Phase 1First-in-HumanADCJapanClinical Development

Related Companies

$TRAX

Read the original article

Published by PR Newswire Pharma on August 3, 2026 1:00 AM

Read Original